Related references
Note: Only part of the references are listed.BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1
Dan Zong et al.
CANCER RESEARCH (2020)
Epigenetic Input Dictates the Threshold of Targeting of the Integrin-Dependent Pathway in Non-small Cell Lung Cancer
Yang Zhang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance
Yanjun Xu et al.
CANCER BIOLOGY & THERAPY (2019)
Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors
Christopher Peter Mill et al.
BLOOD (2019)
Biological and molecular effects of bromodomain and extra-terminal (BET) inhibitors JQ1, IBET-151, and IBET-762 in OSCC cells
Federica Baldan et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2019)
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
Zuan-Fu Lim et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity
Jennifer S. Carew et al.
BLOOD ADVANCES (2019)
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
J. Remon et al.
ANNALS OF ONCOLOGY (2018)
Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression
Zhongyuan Gao et al.
CANCER BIOLOGY & THERAPY (2018)
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
Sun Min Lim et al.
CANCER TREATMENT REVIEWS (2018)
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
Jonathan Welti et al.
CLINICAL CANCER RESEARCH (2018)
MET amplification increases the metastatic spread of EGFR-mutated NSCLC
Simon Baldacci et al.
LUNG CANCER (2018)
Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
Toshimitsu Yamaoka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
AEG-1 induces gastric cancer metastasis by upregulation of eIF4E expression
Shengjie Wu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)
BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma
Wenjing Fu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
D. T. Saenz et al.
LEUKEMIA (2017)
ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia
Liling Wan et al.
NATURE (2017)
Targeting autophagy in cancer
Jean M. Mulcahy Levy et al.
NATURE REVIEWS CANCER (2017)
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
Eiki Ichihara et al.
CANCER RESEARCH (2017)
Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors
Qiang Xiao et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shaokun Shu et al.
NATURE (2016)
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Matthew J. Niederst et al.
CLINICAL CANCER RESEARCH (2015)
Histone Acetylation Enzymes Coordinate Metabolism and Gene Expression
Yuan Shen et al.
TRENDS IN PLANT SCIENCE (2015)
Histone deacetylase inhibitors and cell death
Jing Zhang et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2014)
EGF receptor trafficking: consequences for signaling and cancer
Alejandra Tomas et al.
TRENDS IN CELL BIOLOGY (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
AEG-1 Is a Target of Perifosine and Is Over-Expressed in Gastric Dysplasia and Cancers
Wenbin Huang et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells
Zhuo Ma et al.
CANCER BIOLOGY & THERAPY (2012)
Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression
Teppei Yamaguchi et al.
GENES & DEVELOPMENT (2010)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast
ZH Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Expression profile of histone deacetylase 1 in gastric cancer tissues
JH Choi et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2001)
Share Paper
